Mannkind (MNKD) Other Non-Current Assets (2010 - 2026)
Mannkind (MNKD) reported Other Non-Current Assets of $747000.0 for Q1 2026, down 97.34% year-over-year from $28.1 million in Q1 2025, and down 96.29% on a QoQ basis from $20.1 million in Q4 2025.
Mannkind (MNKD) has 17 years of Other Non-Current Assets data on file, last reported at $747000.0 in Q1 2026.
- Quarterly Other Non-Current Assets fell 97.34% year-over-year to $747000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $747000.0 (down 97.34% YoY) and the FY2025 annual result came in at $20.1 million, down 24.77% from the prior year.
- Other Non-Current Assets eased to $747000.0 in Q1 2026 per MNKD's latest filing, from $20.1 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $28.1 million in Q1 2025 and bottomed at $732000.0 in Q2 2024.
- The 5-year median for Other Non-Current Assets is $12.1 million (2022), against an average of $13.0 million.
- The widest annual swing landed in 2025, when Other Non-Current Assets soared 2580.87%; it then tumbled 97.34% in 2026.
- Tracing MNKD's Other Non-Current Assets over 5 years: stood at $9.7 million in 2022, then decreased by 23.59% to $7.4 million in 2023, then jumped by 260.32% to $26.8 million in 2024, then dropped by 24.77% to $20.1 million in 2025, then sank by 96.29% to $747000.0 in 2026.
- Per Business Quant, the three latest MNKD Other Non-Current Assets figures stand at $747000.0 (Q1 2026), $20.1 million (Q4 2025), and $19.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Mannkind | 1.09 Bn | 956.66 Mn | 82.66 Mn | 747,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 747,000.00 |
| Dec 31, 2025 | 20.13 Mn |
| Sep 30, 2025 | 19.13 Mn |
| Jun 30, 2025 | 19.62 Mn |
| Mar 31, 2025 | 28.06 Mn |
| Dec 31, 2024 | 26.76 Mn |
| Sep 30, 2024 | 735,000.00 |
| Jun 30, 2024 | 732,000.00 |
| Mar 31, 2024 | 7.45 Mn |
| Dec 31, 2023 | 7.43 Mn |
| Sep 30, 2023 | 8.05 Mn |
| Jun 30, 2023 | 8.35 Mn |
| Mar 31, 2023 | 16.38 Mn |
| Dec 31, 2022 | 9.72 Mn |
| Sep 30, 2022 | 17.31 Mn |
| Jun 30, 2022 | 17.51 Mn |
| Mar 31, 2022 | 12.06 Mn |
| Dec 31, 2021 | 8.44 Mn |
| Sep 30, 2021 | 6.09 Mn |
| Jun 30, 2021 | 5.80 Mn |
| Mar 31, 2021 | 3.05 Mn |
| Dec 31, 2020 | 3.27 Mn |
| Sep 30, 2020 | 3.60 Mn |
| Jun 30, 2020 | 4.01 Mn |
| Mar 31, 2020 | 4.35 Mn |
| Dec 31, 2019 | 6.19 Mn |
| Jun 30, 2019 | 200,000.00 |
| Mar 31, 2019 | 51,000.00 |
| Dec 31, 2018 | 249,000.00 |
| Sep 30, 2018 | 199,000.00 |
| Jun 30, 2018 | 320,000.00 |
| Mar 31, 2018 | 368,000.00 |
| Dec 31, 2017 | 300,000.00 |
| Sep 30, 2017 | 480,000.00 |
| Jun 30, 2017 | 523,000.00 |
| Mar 31, 2017 | 609,000.00 |
| Dec 31, 2016 | 16.70 Mn |
| Sep 30, 2016 | 702,000.00 |
| Jun 30, 2016 | 1.25 Mn |
| Mar 31, 2016 | 1.10 Mn |
| Dec 31, 2015 | 13.50 Mn |
| Sep 30, 2015 | 1.83 Mn |
| Jun 30, 2015 | 2.03 Mn |
| Mar 31, 2015 | 2.03 Mn |
| Dec 31, 2014 | 848,000.00 |
| Sep 30, 2014 | 2.11 Mn |
| Jun 30, 2014 | 7.40 Mn |
| Mar 31, 2014 | 8.44 Mn |
| Dec 31, 2013 | 5.52 Mn |
| Sep 30, 2013 | 10.23 Mn |
| Jun 30, 2013 | 230,000.00 |
| Mar 31, 2013 | 230,000.00 |
| Dec 31, 2012 | 230,000.00 |
| Sep 30, 2012 | 230,000.00 |
| Jun 30, 2012 | 230,000.00 |
| Mar 31, 2012 | 230,000.00 |
| Dec 31, 2011 | 230,000.00 |
| Sep 30, 2011 | 230,000.00 |
| Jun 30, 2011 | 230,000.00 |
| Dec 31, 2010 | 317,000.00 |